Bacterioscan Named One Of The Four Medtech Trends To Follow In 2015
St. Louis, MO – 26 May 2015 – BacterioScan Inc. BacterioScan’s 216R Laser Microbial Growth Monitor has been selected as a finalist for the Medical Device Excellence Awards (MDEA) sponsored by Medical Device and Diagnostics Industry Magazine (MDDI) and highlighted as one of the top four medtech trends to follow in 2015. BacterioScan’s industrial design partner is Metaphase, St. Louis, MO. The winner will be announced at a gala dinner in conjunction with the Medical Device & Manufacturing (MD&M) East Conference on June 9th in New York.
Medical Design Excellence Awards (MDEA) calls attention to the most innovative medical devices on the market. “In addition to simply highlighting noteworthy products, the program provides a peek into trends taking hold in the medtech industry”, said BacterioScan’s President and CEO, Dana Marshall. We are honored to be recognized as both a finalist for the MDEA award and as a top medtech trend to follow, by MDDI”.
MDEA identifies several technologies that may help healthcare systems, globally cut costs and improve care by increasing the convenience, speed, and accuracy of diagnoses. The BacterioScan product is targeted toward helping hospitals and clinical microbiology labs rapidly process the approximately 100 million UTI specimens collected each year worldwide. With rapid detection, the BacterioScan system reduces the processing time from several days to less than three hours, delivering a 95% faster time to result for the vast majority of UTI specimens. ‘Additionally, Mr. Marshall says, “the rapid diagnosis of UTI and determination of antibiotic susceptibility can improve the quality of antibiotic therapy selected, reducing the excess or inappropriate use of antibiotics, and reducing opportunities for emergence of antibiotic resistance; all factors that contribute towards lower healthcare costs globally and improved patient care.”
About BacterioScan Inc.
BacterioScan Inc. is an in-vitro diagnostics (IVD) company focused on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan’s instruments can rapidly detect infection, determine if it is resistant to a range of antibiotics, and provide clinicians with patient-specific guidance on the most rapid and cost-effective treatment plan. BacterioScan’s first medical device product is a compact, simple, and low-cost system for rapid detection of Urinary Tract Infection (UTI) for use in clinical microbiology labs. BacterioScan is a privately held global corporation, with headquarters in St Louis, Missouri.
Help employers find you! Check out all the jobs and post your resume.
Medical Design Excellence Awards (MDEA) calls attention to the most innovative medical devices on the market. “In addition to simply highlighting noteworthy products, the program provides a peek into trends taking hold in the medtech industry”, said BacterioScan’s President and CEO, Dana Marshall. We are honored to be recognized as both a finalist for the MDEA award and as a top medtech trend to follow, by MDDI”.
MDEA identifies several technologies that may help healthcare systems, globally cut costs and improve care by increasing the convenience, speed, and accuracy of diagnoses. The BacterioScan product is targeted toward helping hospitals and clinical microbiology labs rapidly process the approximately 100 million UTI specimens collected each year worldwide. With rapid detection, the BacterioScan system reduces the processing time from several days to less than three hours, delivering a 95% faster time to result for the vast majority of UTI specimens. ‘Additionally, Mr. Marshall says, “the rapid diagnosis of UTI and determination of antibiotic susceptibility can improve the quality of antibiotic therapy selected, reducing the excess or inappropriate use of antibiotics, and reducing opportunities for emergence of antibiotic resistance; all factors that contribute towards lower healthcare costs globally and improved patient care.”
About BacterioScan Inc.
BacterioScan Inc. is an in-vitro diagnostics (IVD) company focused on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan’s instruments can rapidly detect infection, determine if it is resistant to a range of antibiotics, and provide clinicians with patient-specific guidance on the most rapid and cost-effective treatment plan. BacterioScan’s first medical device product is a compact, simple, and low-cost system for rapid detection of Urinary Tract Infection (UTI) for use in clinical microbiology labs. BacterioScan is a privately held global corporation, with headquarters in St Louis, Missouri.
Help employers find you! Check out all the jobs and post your resume.